Abstract. Prolonged exposure of the peritoneal mesothelium to high dialysate glucose concentrations reduces anionic sites that are critical to its selective permeability, thereby impairing the peritoneal transport properties in patients on long-term peritoneal dialysis (PD). Perlecan, an anionic heparan sulfate proteoglycan, is pivotal to the selective permeability of basement membranes, and high glucose concentrations modulate its synthesis in mesangial cells. The effect of glucose on perlecan expression in the peritoneal mesothelium has not been established. We investigated perlecan expression in peritoneal biopsies from patients on PD, and the effect of high glucose concentrations on perlecan synthesis in cultured human peritoneal mesothelial cells (HPMC). Peritoneal biopsies from PD patients showed reduced perlecan expression compared with controls. Exposure of HPMC to high glucose concentrations resulted in a dose-dependent reduction in the synthesis of perlecan polypeptide and its deposition into the extracellular matrix. These effects were mediated in part through the induction of TGF-␤1. Characterization studies showed that perlecan synthesized by HPMC contained solely heparan sulfate glycosaminoglycan (HS GAG) chains, and [
Abstract. Prolonged exposure of the peritoneal mesothelium to high dialysate glucose concentrations reduces anionic sites that are critical to its selective permeability, thereby impairing the peritoneal transport properties in patients on long-term peritoneal dialysis (PD). Perlecan, an anionic heparan sulfate proteoglycan, is pivotal to the selective permeability of basement membranes, and high glucose concentrations modulate its synthesis in mesangial cells. The effect of glucose on perlecan expression in the peritoneal mesothelium has not been established. We investigated perlecan expression in peritoneal biopsies from patients on PD, and the effect of high glucose concentrations on perlecan synthesis in cultured human peritoneal mesothelial cells (HPMC). Peritoneal biopsies from PD patients showed reduced perlecan expression compared with controls. Exposure of HPMC to high glucose concentrations resulted in a dose-dependent reduction in the synthesis of perlecan polypeptide and its deposition into the extracellular matrix. These effects were mediated in part through the induction of TGF-␤1. Characterization studies showed that perlecan synthesized by HPMC contained solely heparan sulfate glycosaminoglycan (HS GAG) chains, and [ 35 S]-incorporation studies demonstrated progressive reduction of their de novo synthesis with increasing glucose concentrations (68142 Ϯ 3658, 48147 Ϯ 2517, 31468 Ϯ 5781, and 25575 Ϯ 3621 cpm/g cellular protein for 5 mM, 30 mM, 75 mM, and 120 mM D-glucose, respectively; P Ͻ 0.001 for 5 mM versus 30 mM D-glucose, and P Ͻ 0.0001 for 5 mM versus 75 mM or 120 mM D-glucose). Both the length and the charge density of the HS GAG chains remained unchanged. Reduction of peritoneal perlecan expression in long-term PD was attributed to high dialysate glucose concentrations, which induced TGF-␤1 and reduced perlecan synthesis in HPMC. Since perlecan can sequester growth factors, thereby modulating cell migration and differentiation perturbation of peritoneal perlecan expression contributes to the structural and functional changes of the peritoneum in long-term PD.
The peritoneal membrane comprises an overlying monolayer of mesothelial cells, beneath which lies the interstitium that contains fibroblasts, collagen fibrils, and a capillary network. Mesothelial cells play important roles in both peritoneal transport functions and remodeling, the latter through its controlled synthesis of cytokines, chemokines, growth factors, prostaglandins, and matrix proteins (1) (2) (3) (4) . Injury to the mesothelium represents an important initiating step, leading to the progressive histologic changes of the peritoneum in peritoneal dialysis (PD). The abundant anionic sites normally present in the mesothelium and the underlying basement membrane prevent excessive albumin wastage (5) (6) (7) (8) . Proteoglycans (PG), which are anionic macromolecules present ubiquitously on the cell surface and in basement membrane (9, 10) , are putatively major contributors to the anionic sites in the peritoneum. Glycosaminoglycans (GAG), the highly negatively charged carbohydrate moiety of PG, have been identified in natural peritoneal fluid and serve to reduce friction and prevent adhesion of the abdominal viscera (11, 12) . Moreover, we have previously demonstrated PG synthesis and secretion in human peritoneal mesothelial cells (HPMC) in vitro (13) .
PG are composed of a protein backbone to which one or more GAG chain(s) is/are attached, and they serve multifaceted functions pertaining to filtration and permeability characteristics of biologic membranes, cell adhesion, differentiation, proliferation, sequestration of growth factors, and collagen fibrillogenesis (14, 15) . PG synthesis is modulated by inflammation and chemical or bacterial insult. Long-term PD is associated with chronic inflammation in the peritoneal membrane leading to progressive structural and functional deterioration (16 -18) . Prolonged exposure to high dialysate glucose concentrations is among the important etiological factors leading to these changes. There is accumulating evidence that some of the pathogenetic mechanisms may be similar to those in diabetes mellitus, for example, cell hypertrophy, increased synthesis of transforming growth factor-␤1 (TGF-␤1) and matrix proteins, and increased basement membrane permeability induced by high ambient glucose concentrations (19, 20) . Altered synthesis of perlecan, a large heparan sulfate (HS) PG that plays a critical role in the selective permeability of basement membranes, mitogenesis, angiogenesis, and cell adhesion, has been demonstrated in diabetes mellitus (9) . The effect of glucose on peritoneal perlecan synthesis remains to be elucidated.
We therefore examined in vivo peritoneal perlecan expression in peritoneal biopsies from patients on PD, and we investigated the etiological significance of dialysate glucose and TGF-␤1 on perlecan synthesis in cultured HPMC.
Materials and Methods
All materials were of the highest grade and were purchased from Sigma (Tin Hang Technology Ltd, Hong Kong) unless otherwise stated. Tissue culture flasks were from Falcon (Becton-Dickinson, Gene Company, Hong Kong), and culture media and supplements were from Invitrogen Life Technologies (Hong Kong). TGF-␤1 DuoSet ELISA Development System and TGF-␤1 neutralizing antibody were purchased from R&D Systems (TWC Biosearch International, Hong Kong). Carrier free Na 2 [ 35 S]SO 4 (950 to 1350 Ci/mmol) was purchased from Amersham Biosciences China Ltd, Hong Kong. Perlecan antibodies included a kind gift (EY10) from Professor John Hassell (Tampa, Florida) and one purchased from Zymed (7B5 clone, Onwon Trading Ltd, Hong Kong).
Peritoneal Biopsy Studies
Parietal peritoneal biopsies were obtained with informed consent from five patients at the time of initial insertion of the PD catheter and from six patients who had been on PD for more than 12 mo at the time of catheter re-insertion due to blockade of fluid flow by omentum or malpositioning. Catheter re-insertion biopsies subsequent to previous removal necessitated by severe peritonitis were excluded from this study. Paraffin sections (10 m) were incubated with antibody against perlecan (1:50) overnight at room temperature (18) . Samples were then washed in PBS and incubated with horseradish peroxidaseconjugated secondary antibody for 1 h at 37°C. Signal detection was by the peroxidase-anti-peroxidase (PAP) method (Dako, Gene Company, Hong Kong), with hematoxylin counterstaining and examination under a Leica DMLB microscope (Schmidt BioMed Tech (HK) Ltd, Hong Kong). Specimens were photographed with Kodak Max 100 film using a MP560 camera (Schmidt BioMed Tech (HK) Ltd, Hong Kong). For all biopsies in both sample groups, the staining intensity at six separate points along the length of the mesothelium was measured in a semiquantitative manner using ChemiGenius analysis software (Syngene, Gene Company, Hong Kong), and the mean staining intensity (expressed as arbitrary densitometry unit (DU) calculated for each specimen.
Culture of HPMC
HPMC were obtained by enzymatic digestion of omental specimens from non-uremic patients who underwent abdominal surgery. HPMC were cultured in Medium-199 supplemented with 10% FCS as described previously (13, 18) . All experiments were performed on cells of the second passage that had been growth-arrested for 72 h. In experiments to investigate the effect of physiologic and elevated concentrations of glucose on cell morphology and perlecan expression, HPMC were preconditioned in 5 mM, 30 mM, 75 mM, or 120 mM D-glucose for 2 wk; 30 mM represented the intra-peritoneal glucose concentration after 1 h of equilibration after the instillation of conventional peritoneal dialysis solution, and 75 mM and 120 mM represented the original glucose concentrations in hypertonic dialysates. Mannitol and L-glucose, at concentrations identical to those of D-glucose, were used as the hexose control. To investigate the role of high glucose-induced TGF-␤1 on perlecan synthesis, parallel experiments were performed with the prior addition of TGF-␤1 neutralizing antibody (1 g/ml) or control IgG (1 g/ml) to HPMC for 2 h. Cell morphology was monitored throughout the in vitro culture. HPMC were cultured in 75-cm 2 
TGF-␤1 Secretion by HPMC
Aliquots of supernatant (1 ml) from HPMC (10 6 cells) cultured under control or experiment conditions for time periods up to 48 h were lyophilized and reconstituted in 100 l of H 2 0, and TGF-␤1 was measured with the DuoSet ELISA, which was specific to TGF-␤1 and had a detection range of 15 to 2000 pg/ml.
Assessment of Cell Proliferation
HPMC were cultured in triplicate in 96-well plates under control and experiment conditions until 80% confluent, and growth-arrested was for 72 h. Cell proliferation was monitored for time periods up to 48 h, by the addition of MTT (0.5 mg/ml, final concentration) during the last 4 h (21). The resultant formazan was dissolved overnight in 10% (wt/vol) SDS containing 0.01 M HCl, and the optical density was measured at 595 nm, with a reference wavelength of 690 nm.
Cell Protein Quantitation
HPMC cultured in triplicate in 96-well plates under control or experiment conditions were lysed in 4 M urea buffer containing 20 mM sodium acetate (pH 6.0) and 1% (vol/vol) Triton X-100 (50 l), and the protein concentration was determined using a modified Lowry assay (BioRad, Hong Kong).
Isolation and Western Blot Analysis of Perlecan Core Protein
HPMC were cultured under control or experiment conditions in 10% FCS that had previously been cleared of PG and GAG by passage over a DEAE-Sephacel column (22) . Cell surface and intracellular [ 35 S]-labeled macromolecules (lysate fraction) were extracted with 0.2% (vol/vol) Triton X-100 in 25 mM Tris-HCl, pH 7.5, while [ 35 S]-labeled cytoskeletal/matrix molecules (matrix fraction) were extracted with 4 M urea, 25 mM Tris-HCl, pH 7.5, containing 1% Triton X-100 (22, 23) . Proteinase inhibitors were included in all samples (13) . Ten micrograms of total protein content of each sample was precipitated with ethanolic potassium acetate and then digested with buffer alone, protease-free chondroitin ABC lyase, or a combination of heparinase I, II, and III (22) . Digested samples were denatured in sample buffer at 95°C for 5 min, separated on a 3 to 12% SDS-PAGE acrylamide gel, and transferred onto nitrocellulose membrane using a mini-gel transfer system (Bio-Rad, Hong Kong) at 100 V for 1 h at 4°C. Equal loading of proteins was confirmed by staining of the membranes with 1% (wt/vol) Ponceau S solution. Membranes were immunoblotted with perlecan antibody (diluted 1:1000), and the respective horseradish peroxidase-conjugated secondary antibody (diluted 1:10,000). The bands were visualized by enhanced chemiluminescence (Amersham Biosciences China Ltd, Hong Kong), semiquantitated by densitometry using ChemiGenius analysis software, and expressed as arbitrary densitometric unit unless otherwise stated.
Immunohistochemical Staining HPMC exposed to control or experiment conditions were fixed with cold acetone/methanol (1:1) for 5 min before washing with PBS. Cells were blocked with 3% BSA in PBS for 1 h at room temperature, followed by washing with PBS for 30 min. Cells were incubated with perlecan antibody (diluted 1:100) for 1 h at 37°C in a humidified chamber (24) . HPMC were washed in PBS and then incubated with FITC-conjugated secondary antibody for 1 h at 37°C in a darkened humidified chamber. After washing with PBS, HPMC were mounted with fluorescence mountant (DAKO, Gene Company, Hong Kong), and epifluorescence was viewed using an Axiovert Zeiss 135 inverted microscope (Zeiss, Gold Pacific Ltd, Hong Kong).
Metabolic Labeling and Differential Extraction of [ 35 S]-Labeled Macromolecules
Confluent growth-arrested HPMC were labeled with 50 Ci/ml Na 2 [ 35 S]-sulfate for 24 h in low-sulfate medium as described previously (13) , and the conditioned medium was decanted. Cell surface and intracellular [ 35 S]-labeled macromolecules (lysate fraction) and cytoskeletal/matrix molecules (matrix fraction) were extracted as described previously (22, 23) . Proteinase inhibitors were included in all samples. 35 S]-labeled PG were dialyzed into 8 M urea buffer containing 0.15 mM NaCl and further purified on an Uno Q column, equilibrated in the same buffer, and interfaced with a Biologic Workstation (BioRad, Hong Kong). Samples were washed with 8 M urea buffer containing (a) 0.1 M NaCl (10 ml) and then (b) 0.4 M NaCl (10 ml) before elution of [ 35 S]-labeled PG with urea buffer containing 1.5 M NaCl (15 ml). Fractions (0.5 ml) were collected and monitored for radioactivity by scintillation beta counting. Total eluted [
35 S]-labeled PG were concentrated by ethanolic potassium acetate precipitation in the presence of carrier chondroitin sulfate (50 g/ml) and heparin (50 g/ml), washed with 95% (vol/vol) ethanol, dried under nitrogen, and stored at Ϫ20°C until hydrodynamic size analysis by Sepharose CL-4B or 6B gel filtration chromatography under dissociative conditions.
Gel Filtration Chromatography
To determine the hydrodynamic size of [
35 S]-labeled PG, aliquots of the lysate and matrix fractions from HPMC cultured under control or experiment conditions were treated with either buffer alone, chondroitin ABC lyase, or heparinase I, II, and III (13) and chromatographed on Sepharose CL-4B columns (0.05 ϫ 1.2m) equilibrated in 4 M guanidine-HCl buffer (13) . To confirm the PG nature of the [ 35 S]-labeled molecules, samples were digested with papain (15 U, 100 l) at 60°C overnight, and the enzyme inactivated by the addition of 4 M guanidine buffer (400 l) before gel filtration chromatography. Samples (0.5 ml) were collected at a rate of 2.4 ml/h, and radioactivity was monitored by scintillation beta counting. The void (V o ) and total (V t ) volume of each column was calibrated using dextran blue and unincorporated [ 35 S]-sulfate, respectively. The hydrodynamic size of individual PG/GAG species was calculated using the equation
where V e represented the fraction number of the eluted sample/peak.
Analysis of Perlecan HS GAG Chain Modification
The length and anionic charge of perlecan HS GAG chains synthesized under control and experiment conditions were assessed by gel filtration chromatography and anionic exchange chromatography, respectively.
Altered hydrodynamic size of HS GAG chains was detected by papain digestion to release the HS chains, followed by Sepharose CL-6B chromatography. V o and V t were calibrated as with Sepharose CL-4B.
Changes in electronegativity were detected by applying the samples to a Uno Q column interfaced with a BioRad Workstation, followed by elution with a linear NaCl gradient of 0.15 to 1.5 M in 8 M urea buffer. Fractions (0.5 ml) were collected and monitored for radioactivity. Figure 1 . Representative perlecan expression in peritoneal biopsy specimens (A) from patients before commencement of peritoneal dialysis (PD) or (B) from patients on long-term PD. Paraffin sections were subjected to cytochemical staining using the peroxidase-antiperoxidase (PAP) method. Immunoreactive products were visualized using diaminobenzidine as chromagen and counterstained with hematoxylin. Constitutive expression of perlecan was observed in peritoneal specimens obtained from new PD patients (A), identified predominantly within the peritoneal mesothelium (arrow). Peritoneal specimens from patients on long-term PD (B) demonstrated significant reduction in perlecan expression within the mesothelium, but increased expression within the submesothelium (*). Scale bar, 200 m. The mean intensity staining of perlecan in the mesothelium of each biopsy specimen obtained from patients at the time of initial catheter insertion (E) or catheter re-insertion (F) was analyzed in a semiquantitative manner using ChemiGenius analysis software and its association with submesothelial thickness determined (C). Data represents the mean intensity staining of six separate measurements for each specimen.
Statistical Analyses
Results are expressed as mean Ϯ SD. Unless otherwise stated, all experiments were performed three times using HPMC from four separate donors. Statistical analyses were performed using Prism version 3 GraphPad software (San Diego, CA). Between-group data were compared by the t test. P Ͻ 0.05 was considered statistically significant.
Results

Perlecan Expression in Peritoneal Biopsies
Perlecan expression was prominent in the mesothelium of peritoneal biopsies obtained at commencement of PD ( (Figure 1 , B and C; mean perlecan staining, 25.16 Ϯ 11.83 DU; mean submesothelial thickness, 368.33 Ϯ 42.14 m; P Ͻ 0.001). Long-term PD patients also showed increased perlecan staining in the submesothelial fibrous tissue, compared with the former group ( Figure 1B) .
In in vitro experiments, HPMC were pre-conditioned in either physiologic (5 mM) or elevated (30 mM, 75 mM, or 120 mM) D-glucose concentration for 2 wk. Prior studies had demonstrated that shorter durations of glucose exposure did not alter perlecan synthesis.
Effect of High Glucose Concentrations on HPMC Morphology, Proliferation, and Total Protein Content
HPMC were preconditioned in 5 mM, 30 mM, 75 mM, or 120 mM D-glucose for 2 wk. Under these conditions, the cells became confluent after 7 to 9 d of culture. HPMC cultured in 5 mM D-glucose exhibited a homogenous, epithelial-like, cobblestone appearance (Figure 2A ). In contrast, HPMC became progressively hypertrophic, multi-nucleated, and multi-vacuolated under increasing glucose concentrations (Figure 2, B-D) , while proliferation was reduced (Figure 3) . Total protein synthesis by HPMC remained unaltered under the different glucose concentrations (Table 1) . Mannitol at concentrations identical to D-glucose did not affect HPMC morphology (Figure 2 , E-H), proliferation ( Figure 3B ), or protein synthesis (Table 1 ). Similarly, no change was observed in control cells exposed to L-glucose (data not shown).
Effect of High Glucose Concentrations on TGF-␤1 Secretion
Under physiologic or high glucose concentrations, over 95% of TGF-␤1 secreted by HPMC was in the latent form and necessitated acid-activation for detection. Glucose increased total TGF-␤1 secretion in a time-and dose-dependent manner ( Figure 4A ). Exposure to 30 mM, 75 mM, or 120 mM Dglucose resulted in a significant increase in TGF-␤1 secretion at 24h (2.01 Ϯ 0.23, 3.86 Ϯ 0.13, 3.94 Ϯ 0.45, and 4.14 Ϯ 0.59 pg/g cellular protein for 5 mM, 30 mM, 75 mM, and 120 mM D-glucose, respectively; P Ͻ 0.05 comparing 5 mM and higher glucose levels) and 48 h (2.85 Ϯ 0.17, 4.18 Ϯ 0.27, 4.57 Ϯ 0.64, and 5.28 Ϯ 0.67 pg/g cellular protein for 5 mM, 30 mM, 75 mM, and 120 mM D-glucose, respectively; P Ͻ 0.05 comparing 5 mM and higher glucose levels). Exposure of HPMC to mannitol did not alter TGF-␤1 secretion significantly, compared with 5 mM D-glucose ( Figure 4B ).
Perlecan Core Protein Synthesis
Expression of perlecan core protein was investigated in the lysate and matrix fractions of HPMC exposed to control or experiment conditions. Western blot analysis showed no perlecan polypeptide in the lysate fractions (data not shown), but only in the matrix fractions ( Figure 5 ). Perlecan core protein was not synthesized as free core protein, but solely attached to HS GAG chains ( Figure 5 , compare lanes 1-4 with lanes 9 -12). The expression of perlecan core protein was progressively reduced with increasing glucose concentrations ( Figure  5, lanes 9 -12) . No change was observed with mannitol ( Figure  5, lanes 13-16) .
Localization of Perlecan Expression
Immunohistochemical staining experiments were performed to localize perlecan expression in HPMC cultured under control or experiment conditions for periods up to 2 wk ( Figure 6 ). Perlecan exhibited a perinuclear distribution in HPMC exposed to 5 mM D-glucose for 24 h. In contrast, its deposition within the extracellular milieu was observed after 3 d of culture ( Figure 6B ). After 2 wk, an extensive perlecan matrix was noted ( Figure 6C ). Under high glucose concentrations (30 mM), perlecan expression was significantly reduced in a timedependent manner ( Figure 6, D-F) . Mannitol at corresponding concentrations did not alter perlecan expression ( Figure 6 G-I) .
Other investigators have reported the presence of agrin, another HSPG, in basement membranes (25 5 cpm/g cell protein, respectively). These macromolecules were characterized as PG by a shift in their elution profiles on Sepharose CL-4B under dissociative conditions after papain digestion ( Figure 7 ). Using selective enzymatic digestion, a large HSPG that was resistant to chondroitin ABC lyase but sensitive to heparinase I, II, and III treatment was detected and identified exclusively in the matrix fraction, thereby corroborating our Western blot data. The intact perlecan molecule possessed a hydrodynamic size (K av ) of 0.10 to 0.25 on Sepharose CL-4B. The length of perlecan HS GAG chains was unaltered in the presence of elevated glucose concentrations, as demonstrated by papain treatment followed by gel filtration chromatography on Sepharose CL-6B ( Table 2 ). The charge density of these macromolecules was also unchanged (data not shown).
The Role of Glucose-Induced TGF-␤1 on Perlecan Synthesis
Experiments were performed in which HPMC were exposed to physiologic or high glucose concentrations in the presence or absence of TGF-␤1 neutralizing antibody or control IgG (1 g/ml), followed by Western blot analysis and immunohistochemistry. Since 30 mM D-glucose represented the intraperitoneal glucose concentration after equilibration of dialysate, subsequent series of experiments concentrated on this glucose concentration.
TGF-␤1 neutralizing antibody or control IgG per se did not alter perlecan core protein expression in HPMC cultured under 5 mM D-glucose (Figure 8, compare lanes 7-9) . While control IgG did not alter perlecan expression in HPMC exposed to 30 mM D-glucose, TGF-␤1 neutralizing antibody partially restored perlecan core protein synthesis in these cells (Figure 8,  lanes 10 -12) . These results were corroborated by immunohistochemical studies, which showed that TGF-␤1 neutralizing antibody increased extracellular perlecan expression under 30 mM D-glucose ( Figure 9 ).
Discussion
The mesothelium is the most extensive serous membrane in the body. It contains abundant anionic sites and intercellular junctions that enable it to act as a biologic barrier to the passage of plasma molecules (26, 27) . The introduction of PD over 20 yr ago has allowed us to manipulate the peritoneal membrane to act as a dialyzing organ in which ultrafiltration and diffusion occurs. The constant exposure of the mesothelium to unphysiological PD solutions, however, results in the progressive deterioration of the peritoneal membrane, with subsequent loss of peritoneal function and selective regulation of molecules. Possible mechanisms of peritoneal dysfunction include the altered expression of intercellular junctions (tight junctions, gap junctions, adherens junctions, and desmosomes) within the mesothelium. This has been highlighted in a recent study by Ito et al. (27) , who demonstrated an inverse association between elevated glucose induction of TGF-␤1, and synthesis of proteins that constitute intercellular junctions, namely ZO-1, E-cadherin, and ␤-catenin. Increased transperitoneal passage of proteins as a result of reduced anionic sites 35 S]-labeled perlecan was purified from the matrix fraction as described in the methodology and digested with chondroitin ABC lyase, and the resultant material was characterized by gel filtration chromatography on Sepharose CL-4B under dissociative conditions (see Figure 7 for representative elution profiles). HS GAG were chromatographed on Sepharose CL-6B to determine their molecular radius (K av ). Results are expressed as mean Ϯ SD of four separate experiments. within the mesothelium and the underlying basal lamina by chemical or bacterial injury has also been documented (7, 8) .
The constituents contributing to these anionic sites, or their change during PD, have not been defined. Perlecan has a strong net negative charge and is a ubiquitous macromolecule in basement membranes. We therefore investigated its expression in the normal peritoneal membrane and that under the influence of peritoneal dialysate. Our original observations showed intense perlecan expression in peritoneal biopsies from patients at the commencement of PD, before exposure to peritoneal dialysates. In contrast, mesothelial perlecan expression was significantly reduced in chronic PD patients and was associated with thickening of the submesothelium. That perlecan expression within the mesothelium is decreased during clinical PD is in accordance with the observation from Shostak et al. (28) , who demonstrated reduced charge density in rat mesothelium during experimental PD, accompanied by increased permeability to plasma protein.
Perlecan is a large PG that possesses either HS or CS GAG chains, and it has a wide tissue distribution. Apart from conferring selective permeability through its negative charge, there are recent data to substantiate an important role of perlecan in maintaining the mechanical and functional integrity of basement membranes (29) . Perlecan expression is often changed in diseases that affect the basement membrane. In diabetic mellitus, the altered perlecan expression in the kidney is related to hyperglycemia (9, 30) . It is therefore pertinent to examine the effect of high dialysate glucose levels on peritoneal perlecan expression.
HPMC cultured in vitro provide a means to study the effects of peritoneal dialysate on cell proliferation and synthesis of macromolecules. Previous studies have demonstrated that in vivo morphologic and immunohistochemical characteristics were preserved in cultured HPMC (31) . Our results showed constitutive synthesis of perlecan by HPMC under physiologic glucose concentration. The perlecan thus synthesized had a hydrodynamic size of 0.15 to 0.25 (on Sepharose CL-4B), comprising a core protein of M r approximately 173 kD and exclusively HS GAG chains of approximately 30 kD. Differential cellular extraction, Western blot analysis, and immunohistochemistry demonstrated perlecan deposition in the extracellular matrix at confluence of HPMC. Exposure of HPMC to increasing glucose concentrations progressively reduced de novo perlecan synthesis, while there was no qualitative change in the core protein or GAG chains. This quantitative reduction in perlecan synthesis was selective, since total cell protein synthesis remained unaltered. In addition, these changes were specific to high concentrations of D-glucose and not related to osmolality, as indicated by the results with mannitol. In view of the unaltered anionic charge density and the length of GAG chains, a reduction in GAG synthesis was the likely mechanism leading to the decreased sulfate incorporation under the influence of high glucose concentrations. Other investigators have demonstrated altered perlecan synthesis in glomerular cells and perlecan deposition in glomerular basement membrane (GBM) upon exposure to supra-physiologic glucose concentrations (32, 33 ). An overall reduction in HSPG with preservation of the charge density and the length of GAG chains has been noted within the diabetic GBM or glomerular epithelial cells, similar to our findings in HPMC (33) (34) (35) (36) . However, van Det et al. (37) have reported reduced sulfation of the HS GAG chains but unaltered HSPG core protein synthesis in mesangial and epithelial cells upon exposure to elevated glucose concentrations. While the biologic implications of reduced GAG chain synthesis or under-sulfation of GAG chains remain to be fully elucidated, these changes could have important implications on cell proliferation, differentiation, or activation, and angiogenesis, since the GAG moiety of perlecan engages in the coupling of growth factors and affects their stability, conformation, proteolysis, and sequestration (38) . These indirect wide-ranging effects of perlecan are further underscored by the recent data that showed that its core protein exhibited similar growth factor sequestration actions (39) .
Fibroblasts and endothelial cells synthesize perlecan core protein with apparent M r of 400 to 470 kD (40, 41) , while the core protein synthesized in mesangial cells is of M r 250 to 300 kD (22) . We observed that the perlecan core protein synthesized in HPMC was significantly smaller (M r , 173 kD). The relatively lower M r was not attributed to protease digestion during its isolation because proteinase inhibitors were incorporated in all procedures, nor was it the result of internal degradation since de novo synthesis of [ 35 S]-methionine labeled perlecan core protein gave identical results (Yung and Davies, unpublished data). The core protein of perlecan comprises five distinct domains: HS attachment domain, LDL-like domain, two different laminin domains, and N-CAM-like domain that contains potential alternative splicing sites, thereby generating variations of the perlecan molecule (42) . Size variants of perlecan have been observed in the Engelbreth-HolmSwarm tumor matrix (43, 44) , and alternative splicing has been demonstrated in the nematode homologue of mammalian perlecan UNC-52 and mouse skeletal muscle cells (45) . It is thus possible that alternative splicing or posttranscriptional modification in HPMC may result in a truncated form of perlecan with smaller molecular weight. In this context, we have previously demonstrated that HPMC constitutively synthesized stromelysin (46) , an enzyme that degraded the core protein of proteoglycans, thereby releasing GAG-peptide fragments.
The role of TGF-␤1 in mediating the glucose-induced changes in perlecan synthesis is exemplified by the results obtained with TGF-␤1 neutralizing antibody and the induction of TGF-␤1 secretion by HPMC in the presence of high glucose concentrations. The latter has also been shown in other cell types (47, 48) . Iozzo et al. (49) have demonstrated TGF-␤1-responsive sequences between Ϫ461 and Ϫ285 bp in the promotor region of human perlecan, which could explain the effect of exogenous TGF-␤1 on perlecan expression in human colon carcinoma cells, uterine epithelial cells, aortic endothelial cells, and corneal fibroblasts (47, 48) . We and others (50 -52) have demonstrated that TGF-␤1 was secreted predominantly in the inactive or latent form in HPMC, and activation could be achieved by an increase in temperature, extreme pH, altered glycosylation, integrin binding, plasmin, reactive oxygen species, or thrombospondin-1. The exact mechanism involved in TGF-␤1 activation in HPMC is undefined. Thromobspondin-1 plays a pivotal role in high-glucose-induced TGF-␤1 activation in mesangial cells (52) . Vischer et al. (53) have shown that perlecan binds thrombospondin-1 through its HS GAG chains, thus sequestering this glycoprotein at the apical surface of endothelial cells, before its internalization through receptor-mediated endocytosis. It is therefore appropriate to investigate whether perlecan may modulate the activation of TGF-␤1 by presenting a high local concentration of thrombospondin-1, thereby implicating a two-way relationship between perlecan and TGF-␤1.
In summary, we have presented novel evidence that the normal peritoneal membrane expresses perlecan, which is synthesized by HPMC, and that perlecan synthesis decreases after exposure to high glucose concentrations, leading to the reduced perlecan expression in patients on PD. The interrelationship between perlecan, TGF-␤1, and high dialysate glucose concentrations, together with the indirect effects of perlecan on cellular migration and differentiation, represent pathogenetic mechanisms leading to the progressive structural and functional alterations of the peritoneal membrane during long-term PD.
